FDA Failed to Protect Women From Unwanted and Dangerous Abortions: Elliot Institute Amicus Brief

David C. Reardon
February 29, 2024
Reproduced with Permission

The Food and Drug Administration's (FDA) approval of the abortion drug, mifepristone, negligently exposed millions of women to unwanted, unsafe, and unnecessary abortions, according to an amicus brief filed by the Elliot Institute, Rachel's Vineyard, and Entering Canaan Ministry.

The brief details the Clinton administration's political goals and social engineering agenda when the president ordered for the FDA to bring the abortion drug to the American marketplace.

To comply with this order, the FDA waived the normal requirements for double blind trials proving that measurable benefits of the drug exceeded any negative outcomes. In addition, the FDA narrowed its range of interest, only considering how often the drug successfully induced abortions that did not require additional surgical intervention.

All evidence demonstrating that abortion contributes to emotional and mental health injuries in women, before and after the drug was approved for distribution, were waived aside as irrelevant. All evidence of risks associated with abortion in general, and chemical abortions in particular, have been consistently ignored.

Moreover, the FDA normally requires drug manufacturer's to identify the subset of patients for whom any drug is contraindicated. For example, if a drug is more likely to carry negative effects for persons who have diabetes, this warning should be given to both doctors and patients.

But when dealing with abortion drugs, the FDA has maintained the unfounded position that the abortion is perfectly safe for every woman and in every circumstance. But this conclusion is not supported by clinical trials, much less double blind trials. It is simply based on untested presumption that "if a woman wants an abortion, it is a good thing to give her one."